A 3-year open-label study to describe long term changes in ganglion cell/inner plexiform layer (GCIPL) thickness in patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate using optical coherence tomography (OCT)

Trial Profile

A 3-year open-label study to describe long term changes in ganglion cell/inner plexiform layer (GCIPL) thickness in patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate using optical coherence tomography (OCT)

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms VISION
  • Sponsors Biogen
  • Most Recent Events

    • 22 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 25 Aug 2015 New trial record
    • 23 Jun 2015 Trial design presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top